RecruitingNCT06494826

Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease


Sponsor

Weizmann Institute of Science

Enrollment

40 participants

Start Date

May 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

In this study, the investigators will explore our protein-based platform assessing commensals potentially contributing to features of CD, while assessing the global composition and abundance of AMPs expressed in the GI tract under specific CD-relevant clinical contexts. This would enable us to (a) identify new commensals contributing to features of CD spectrum and various sub-types; (b) uncover the mechanistic basis of dysbiosis in CD (c) utilize the pipeline to develop new theranostic for disease exacerbation, complication and treatment responses; and (d) potentially enable future exploitation of novel AMP combinations, and their respective antimicrobial capacity to counteract dysbiosis in CD. Uncovering the proteomic manifestations of perturbed host-microbiome communications in CD will eventually enable the development and validation of clinical non-invasive surrogate markers, mechanistically determine causative drivers of CD, and potentially facilitate the development of novel therapeutic interventions.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting tissue and fluid samples from the gut during colonoscopy to study how proteins produced by the body and gut bacteria may influence the development and behavior of Crohn's disease — a chronic inflammatory bowel condition. **You may be eligible if...** - You are 18 or older - You are scheduled for a medically necessary colonoscopy due to suspected new-onset Crohn's disease - You have not yet received any medical or nutritional treatment for Crohn's disease - OR: You are a healthy volunteer undergoing colonoscopy for routine screening or non-specific gut symptoms **You may NOT be eligible if...** - You already have a confirmed diagnosis of inflammatory bowel disease and have previously been treated - You have other serious gastrointestinal diseases - You are unable to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERcolonoscopy procedure

Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention. colonoscopy will not be done for research purposes only .


Locations(1)

Emek medical center

Afula, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06494826


Related Trials